azp-3601
Peptideexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 7, 2020 (NCT05239221)
Timeline
Indications
Mechanism of action
- Parathyroid hormone receptorANTAGONIST
Parathyroid hormone receptor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095311 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05778071 | Phase 3 | Jun 7, 2023 | Amolyt Pharma |
| NCT05239221 | Phase 1 | Sep 7, 2020 | Amolyt Pharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amolyt Pharma | For profit | 2 | 2 | 2 | 2020 |
1 organizations
Page 1 / 1